The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1481
November 9, 2015
View Complete Issue         Table of Contents 2019 
Two Long-Acting Injectable Antipsychotics for Schizophrenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two Long-Acting Injectable Antipsychotics for Schizophrenia
November 9, 2015 (Issue: 1481)
The FDA has approved two new long-acting injectable formulations of second-generation antipsychotics for treatment of schizophrenia: aripiprazole lauroxil (Aristada – Alkermes), which is given once every 4-6 weeks, and paliperidone palmitate...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two Long-Acting Injectable Antipsychotics for Schizophrenia
Article code: 1481b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.